Issuance of new us patent bolsters ip protection for jaguar health in the treatment of short bowel syndrome (sbs)

New patent issued for core rare disease target indication for crofelemer jaguar is supporting investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of sbs and microvillus inclusion disease in the us, eu, and middle east/north africa regions, with results expected before the end of 2023 and in 2024 san francisco, ca / accesswire / november 1, 2023 / napo pharmaceuticals (napo), a jaguar health (nasdaq:jagx) (jaguar) family company, today announced that the united states patent and trademark office on october 10, 2023 issued a new u.s. patent to napo for methods for treating short bowel syndrome (sbs), bile acid diarrhea, and diarrhea associated with small intestine resection or gallbladder removal, in patients with an inhibitor of chloride-ion transport such as crofelemer, napo's novel plant-based prescription drug. "we are very happy that this patent has been issued and believe that it further enhances our intellectual property protection for crofelemer for our core rare disease target indication of sbs," said lisa conte, jaguar's founder, president, and ceo.
JAGX Ratings Summary
JAGX Quant Ranking